Iran’s knowledge-based firm Nanodaru Bojohan Pardis has brought its antibody drug conjugate Tadrox to full production and is preparing for Phase III trials. Early data indicate markedly higher efficacy, delayed disease progression up to sixfold and far fewer side effects, while local manufacturing cuts treatment costs to under 10% of comparable imported therapies.
Tehran: Nanodaru Bojohan Pardis, a knowledge-based Iranian company, announced a significant breakthrough in oncology with its advanced drug Tadrox, designed for the treatment of breast and gastrointestinal cancers. The therapy is an antibody drug conjugate (ADC): a targeted platform in which a monoclonal antibody delivers a potent cytotoxic payload directly to tumor cells, boosting efficacy and minimizing off-target toxicity compared with conventional chemotherapy.
According to Ali Aghajani, the company’s Business Development Director, Tadrox has reached full production and, after receiving its ethics approval, is ready to enter Phase III clinical studies. Interim clinical evidence shows the medicine can delay relapse and clinical deterioration by up to six times, translating into a substantial improvement in patients’ life expectancy.
Aghajani noted that the project one of the few locally capable of matching top global developers in ADC technology has benefited from 48 billion tomans in tax facilities, allowing the company to channel more resources into R&D. He emphasized the heavy research burden and technical complexity of ADCs, citing high costs for sourcing reference branded comparators for trials, specialized raw materials and equipment, and the need for highly skilled personnel.
Crucially, domestic manufacturing has slashed costs: the price of Tadrox is less than 10% of a similar imported product, improving affordability and helping retain foreign currency. The company reports that the therapy’s targeted mechanism significantly reduces adverse effects while enhancing therapeutic impact, positioning Tadrox as a front-runner in modern cancer care in Iran.